Allopurinol Adjuvant Therapy in Patients With Major Depressive Disorder
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 70
- 试验地点
- 2
研究概览
简要总结
Major depressive disorder (MDD) is one of the most common psychiatric disorders with serious socioeconomic consequences on daily life and health care costs. Despite the advent of newer antidepressants that target monoamine pathways, nearly 50% of patients have no response to first-line antidepressant therapy. Thus, a combination of medications with different strategies at the beginning of treatment could provide further therapeutic benefits to MDD patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
盲法说明
double-blinded
入排标准
- 年龄范围
- 18 Years 至 60 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients aged greater than 18 years old. Patients with a HAM-D score of at least 10 with item 1, depressed mood, scoring 2 or greater, are eligible.
排除标准
- •Patients with bipolar I or bipolar II disorder Patients with eating disorders Pregnant women or women not using medically accepted means of birth control Cardiovascular disorders Severe renal impairment
研究组 & 干预措施
Allopurinol group
35 patients will receive 50 mg/day of sertraline plus allopurinol (300 mg/day).
干预措施: Sertraline 50 MG (Drug)
Allopurinol group
35 patients will receive 50 mg/day of sertraline plus allopurinol (300 mg/day).
干预措施: Allopurinol 300 MG (Drug)
Control group
35 patients will receive Sertraline 50 mg/day plus a placebo.
干预措施: Sertraline 50 MG (Drug)